Merck & Co., Inc. Shares Fall by 4.06% at Close
Merck & Co. continues its downward trajectory on Wall Street. The pharmaceutical manufacturer closed Monday down 4.06%, adding to losses accumulated over the week. The stock is performing well below Wall Street analysts' targets, faced with ongoing challenges related to its business concentration and market turbulence in China.
Stock Performance and Market Reaction
The stock closed at $82.49, marking a 4.06% drop from the previous session. This day's decline is part of a broader downward trend, as Merck has seen a 6.26% decrease over the past week. Over a longer horizon, the stock has lost 19.02% over the past twelve months, a performance starkly contrasting with the Dow Jones, which has gained 11.30% during the same period. This discrepancy highlights the stock's deteriorated position among its peers and the market's doubts about its ability to generate profitable growth. The company's market capitalization stands at $211.02 billion. The trading volume for the day reached 13.78 million shares, representing 0.55% of the company's floating capital. This level of liquidity illustrates mixed interest in the stock, with market participants adopting a cautious stance towards the laboratory's prospects. For comparison, the benchmark Dow Jones index ended down moderately by 0.14%, at 46,694.97 points. Although Merck is a component of this blue-chip index, the stock did not benefit from the relative stability of the overall market. This divergence reflects specific concerns about the company's trajectory, independent of the general mood of the American markets. Since the beginning of 2025, Merck's stock has recorded a loss of 13%, significantly higher than the 5% gains observed in the healthcare sector according to the specialized index.
Quarterly Financial Results and Market Response
The recent publication of third-quarter results provided mixed signals. Quarterly revenue amounted to $17.28 billion, exceeding Wall Street expectations by $320 million, which were aligned at $16.96 billion. Adjusted earnings per share reached $2.58, surpassing the analyst forecast of $2.35 by 23 cents. These outperformances could have supported the stock, especially since Merck had met its profitability commitments in terms of EPS in each of the previous eight quarters. However, this announcement did not resonate positively with the market. Analysts heavily weighed the group's dependence on Keytruda, its flagship cancer treatment, which accounts for more than 47% of total revenue. Keytruda's sales grew by 10% to $8.1 billion for the quarter, a development in line with forecasts but insufficient to alleviate concerns regarding the laboratory's commercial exposure. Meanwhile, Gardasil, the human papillomavirus vaccine, experienced a significant downturn. Sales fell to $1.75 billion for the quarter. The Chinese market remains degraded: the company did not deliver any batches to the market during the quarterly period, as local distributors continued to clear their stocks following a decline in demand caused by regional economic tensions. This prolonged commercial pause, extended until the end of 2025, adds further uncertainty to the group's growth profile. The picture Merck presents to the markets remains that of a company in search of alternative drivers to Keytruda before the arrival of cheaper biosimilars expected in the coming years.
